Satellos Bioscience Inc. Common Stock
MSLE
Get informed when a big investor buys or sells
+ FollowMarket Cap$12.56M
Close$
$5.81
40.6% downside
Current Fair Value
40.6% downsideOvervalued by 40.6% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $12.56 Million |
|---|---|
| Enterprise Value | $5.18 Million |
| Dividend Yield | $- (-) |
| Earnings per Share | $-20.4 |
| Beta | 1.17 |
| Outstanding Shares | 20,831,350 |
Return
| Return on Equity | -57.12% |
|---|---|
| Return on Assets | -52.03% |
| Return on Invested Capital | -59.12% |
Valuation & Multiples
| P/E Ratio | -4.81 |
|---|---|
| PEG | -4.64 |
| Price to Sales | - |
| Price to Book Ratio | 4.9 |
| Enterprise Value to Revenue | - |
| Enterprise Value to EBIT | -0.15 |
| Enterprise Value to Net Income | -1 |
| Total Debt to Enterprise | 0 |
| Debt to Equity | 0 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
August 13, 2026
EPS Estimate
$-0.38
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationNext Earnings Call
Expected Date
November 13, 2026
EPS Estimate
$-0.59
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.00000% |
|---|---|
| Total Calls | - |
| Total Puts | - |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 36.89%▼ 4.32% |
|---|---|
| Total Invested | $59.58M▲ 39.23% |
| Investors Holding | 26▼ 5.00% |
ESG Score
No data
About Satellos Bioscience Inc. Common Stock
14 employees
CEO: Francis Gleeson Satellos Bioscience, Inc. is a regenerative medicine company, which engages in developing novel therapeutics. It operates through a proprietary technology platform, MyoReGenX™ and Leveraging MyoReGenX™, which identify stem cell based reg...